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Background
Outpatient parenteral antimicrobial therapy (OPAT) is defined as the
administration of parenteral antimicrobials in at least two doses given on different
days and without a hospitalization between.1 Rather than a patient being required
to remain in a hospital solely to receive antimicrobial therapy after medical
discharge, he or she can complete a portion of the therapy as an outpatient. The
ability to discharge a patient on intravenous (IV) antimicrobial therapy has been
shown to potentially reduce the high costs associated with chronic administration
of antibiotics,2 increase the patient’s quality of life by granting improved flexibility
and convenience, and reduce the likelihood that the patient will acquire a
nosocomial infection.2 As a result, OPAT has grown at a breakneck pace since its
inception in the 1970s, and projections of its market share predict that it will soon
reach the multibillion-dollar-a-year threshold.1
Interprofessional collaboration and careful selection of patients designated
to receive OPAT are critical to ensuring successful therapy. Beyond the clinical
expertise offered by infectious diseases (ID) physicians, coordination of social
support and third-party authorizations between case management and pharmacy
contribute significantly to a patient’s ability to receive appropriate therapy. In some
cases, the provision of home-based OPAT services can prevent an otherwise
medically unnecessary stay at a subacute rehabilitation facility to receive IV
antimicrobials for patients without reliable transportation to an infusion center.
Additionally, in patients for whom adequate monitoring and follow-up cannot be
guaranteed, complications related to vascular access devices and adverse drug
reactions can lead to significant harm.3 Both social and medical evaluations should
therefore be integral in the process of identifying patients appropriate to receive
OPAT.
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Furthermore, input from pharmacists to assist in the appropriate selection
of antimicrobials and of durations of therapies has the potential to stem the rising
tide of resistant microorganisms. The interventions related to spectrum and duration
can lead to vastly reduced rates of adverse effects due to unnecessary antimicrobial
use and can also reduce the likelihood that the patient may encounter an infection
caused by a resistant organism later in life.4 Additionally, it may reduce the rate of
multidrug-resistant organisms, which is especially critical for patients who must be
admitted but are also most at risk. Through appropriate recommendations related
to the spectrum and duration of therapy, selection of resistant microorganisms can
be minimized, which partially mitigates these risks.
In November 2016 at a community hospital, a dedicated pharmacist was
hired to continue to build a formal OPAT program for all patients discharged on IV
antimicrobials under the care of the ID physician group. Through a collaborativepractice agreement, the pharmacist’s responsibilities upon consultation were to
evaluate and create a plan with recommendations related to antimicrobial selection
(including drug, dose, route, frequency, and duration) as well as monitoring
parameters. The pharmacist also provided patient education and assistance to case
managers involved with disposition planning. Upon patients’ discharge from the
hospital, the pharmacist continued weekly monitoring throughout the duration of
therapy of all patients who received such consultative services during their inpatient
stay. Because of the relatively new nature of this OPAT program and the number
of “good catch” events—in which a potential medical error related to the therapy
or monitoring was prevented—observed since the program’s formal inception, this
study sought to examine the impact of an OPAT program for those patients
receiving OPAT at hospital discharge.
Methods
This was a retrospective observational cohort study examining patients with
an order for an IV antibiotic following discharge from a community hospital within
the period of December 1, 2016, to May 31, 2017. Patients who received OPAT
consults during their index hospital stay were compared to those patients who did
not receive consults in the same period. Only adult patients were included in this
study. Patients residing in a nursing home or long-term care facility prior to
admission and those also receiving oral antimicrobials were excluded from the
analysis. The primary objective was the proportion of patients in each group
readmitted within 30 days of discharge and OPAT initiation, which was stratified
by the reason for readmission (ID process, adverse drug event, or unrelated reason).
17
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Baseline demographic information collected included age, sex, weight, and length
of stay prior to discharge. Type of infection, antimicrobial selection (including
agents with antipseudomonal activity or requiring therapeutic drug monitoring),
duration of treatment, and disposition at hospital discharge were also collected from
the electronic medical record. As avoiding unnecessary short-term acute
rehabilitation (SAR) stays in cases where therapy can be altered and coordinated
with home healthcare is one potential benefit of OPAT, change in disposition from
admission to discharge was also collected.
Statistical Analysis
The Fisher’s exact test and chi-square analyses were utilized as appropriate
for nominal endpoints including the 30-day readmission rate, use of each
antimicrobial class, and use of agents with a high risk for a Clostridioides difficile
infection, such as ceftriaxone, or requiring therapeutic drug monitoring. The
Wilcoxon rank-sum test was utilized to determine the significance of differences in
length of stay and duration of therapy. Statistical Package for the Social Sciences
(SPSS) software was utilized for these analyses. All other variables and baseline
demographic information were described utilizing descriptive statistics.
Results
No statistically significant differences between groups were seen in terms
of demographic information (Table 1).
OPAT Consult
(n = 95)
Median Age (IQR)
Sex (%)
M
F
Median Weight
(IQR)
Median Index LOS
(IQR)
Table 1. Patient Demographics

p Value

61 (21)

No OPAT
Consult
(n = 22)
63 (26)

42 (44)
53 (56)
91 kg
(35 kg)
6 (5)

6 (27)
16 (73)
79 kg
(41 kg)
7 (8)

0.146

18

0.503

0.085
0.313
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No statistically significant difference between the readmission rates of the
OPAT consult group and the non-consult group was observed; however, the rate
for the former was less than half of the latter, numerically (14.73% vs. 31.82%, p =
0.07). Additionally, the proportion of patients requiring a change in disposition did
not vary significantly between groups (Table 2), with 39 (41%) patients with a
consult and 12 (55%) patients without a consult being discharged to a SAR center
or extended-care facility (ECF; p = 0.252). Bacteremia associated with various
sources of infection was the most common type of infection requiring IV therapy
in both groups, constituting 35% of patients in the OPAT consult group and 59%
of the patients without a consult. Differences in provider type and indication for
therapy between groups were statistically significant (p < 0.0001; 3 x 10–12). The
median total days of therapy for patients with a consult was 24, in comparison to
25 in the non-consult group (p = 0.095).

Disposition Change
Indication for Therapy
Empyema
Osteomyelitis
Bacteremia
Intra-Abdominal Infection
Skin and Soft Tissue
Infection (SSTI)
Other
Primary Provider Type
Pulmonary
Cardiology
Surgery
Internal Medicine
Oncology
Median Days of Therapy
(IQR)

OPAT Consult
(n = 95)

No OPAT
Consult
(n = 22)

p Value

39 (41%)

12 (55%)

0.252
3 x 10–12

7
11
33
10

2
2
13
3

25
9

0
2

5
10
25
52
3

7
1
4
8
2

24 (19)

25 (17)

0.000095

0.095

Table 2. Disposition Change, Therapy Indication, and Provider Type, All Patients
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The most significantly differing trends between groups were evident in
prescribing practices. The usage of antipseudomonal coverage was significantly
lower in the OPAT consult group (39.58% vs. 86.36%, p = 0.00006). Additionally,
utilization of ceftriaxone, known for its potential to predispose patients to C.
difficile infections, was also significantly lower in the OPAT consult group (9.47%
vs. 45.45%, p = 0.00004). Differences in other key antibiotics that serve as
stewardship targets were also seen with piperacillin-tazobactam, cefepime, and
vancomycin (Table 3). Also of interest, patients without an OPAT consult who
were discharged to a SAR center or ECF were significantly more likely to have
been prescribed agents requiring therapeutic drug monitoring (100% vs. 59.56%, p
= 0.038) and to have later required readmission (54.55% vs. 16.22%, p = 0.001).
Drug Choice

Ampicillin
Ampicillin-Sulbactam
Piperacillin-Tazobactam
Cefazolin
Ceftazidime
Ceftriaxone
Cefuroxime
Cefepime
Meropenem
Ertapenem
Gentamicin
Tobramycin
Vancomycin
Linezolid
Daptomycin
Metronidazole
Clindamycin
Fluconazole
Antipseudomonal
Agents

OPAT Consult
(n = 95)
5
12
13
15
1
9
1
10
8
4
6
0
39
0
1
2
2
2
37

Table 3. Therapeutic Drug Choice, All Patients
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No OPAT
Consult
(n = 22)
2
2
11
3
0
10
1
7
5
1
5
4
19
2
0
5
2
2
19

p Value

0.495
0.645
0.0001
0.801
0.203
0.00004
0.255
0.011
0.054
0.944
0.017
0.0002
0.0001
0.023
0.213
0.0002
0.104
0.104
0.00006
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Readmitted Subgroup
When examining readmitted patients as a subgroup, several differences
between those receiving a consult and those without were seen (Table 4).
Significant differences in the indications for therapy (p = 0.009) were seen in this
population, with bacteremia and SSTIs as the most common infection types in the
OPAT consult (71%) and non-consult (43%) groups, respectively. Additionally, a
trend was seen showing that patients in this subgroup without a consult were more
likely to have experienced a change in disposition (85.71% vs. 42.86%, p = 0.061).

Median Age (IQR)
Sex
Male
Female
Indication for Therapy
Osteomyelitis
Bacteremia
Intra-Abdominal
Infection
Skin and Soft Tissue
Infection (SSTI)
Other

OPAT Consult
(n = 14)

No OPAT Consult
(n = 7)

p Value

61 (16)

64 (26)

0.711

8
6

5
2

0.525
0.009

2
3

1
5

2

1

6
1

0
0

6 (2)

7 (3)

0.352

12 (14)

9 (6)

0.368

8
6

1
6

Disposition Change

6 (43%)

6 (86%)

0.061

Median Total Days of

28 (24)

28 (27)

0.190

Median Index Length of
Stay in Days (IQR)
Median Days to
Readmission (IQR)
Disposition at Discharge
Home
ECF or SAR

0.061
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Therapy (IQR)
Reason for Readmission
ID Process
Adverse Drug Event
Unrelated Process

0.216
2
3
9

3
1
3

Table 4. Readmitted Patients

Discussion
No statistical significance in terms of the primary objective (30-day
readmission rate) was seen in the study; however, the more than twofold difference
in readmission rate can certainly be seen as clinically significant. The readmission
rate of 14.74% was also similar to the 21.5% readmission rate reported by another
study, which somewhat adds to the confidence with which the results from this
study can be interpreted.5
Considerable improvements in antimicrobial stewardship were seen when
comparing the group of patients receiving a consult to those who did not. This
enhancement in stewardship was primarily via reduced utilization of
antipseudomonal coverage, vancomycin, and ceftriaxone, which demonstrated the
key role that such programs can have on selecting therapy with an appropriately
narrow spectrum. One way by which OPAT can reduce costs and improve patient
outcomes comes via the involvement of ID specialists to improve the selection of
appropriately narrow-spectrum antimicrobials. By avoiding the use of overly broad
coverage, the risk of off-target eradication of the gut microbiome and subsequent
development of a C. difficile infection can be significantly reduced. Beyond the
clinical impact of this variety of infectious diarrhea, C. difficile’s propensity for
toxin production leads to 4.8 billion dollars in additional costs to hospitals in the
United States annually.6 For example, unnecessary use of ceftriaxone, a
cephalosporin utilized for a variety of infections, has become one of many potential
targets for antimicrobial stewardship programs because of its common use and
propensity for causing this type of infection.6,7 It is imperative that therapies be
selected appropriately to cover only the types of microorganisms likely to be
causing the patient’s infection and that therapies be narrowed when culture and
susceptibility data are available. This is a major point of potential impact for
pharmacist-led OPAT services.
22
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The difference in readmissions seen for patients without a consult sent to a
SAR center or ECF may hint at a potential positive influence seen with the inclusion
of a dedicated ID clinical pharmacy specialist to coordinate careful monitoring
during the course of OPAT. Especially when utilizing agents requiring therapeutic
drug monitoring, such as vancomycin or aminoglycosides, the potential for
significant adverse effects is considerable. Additionally, poor availability of lab
data during the course of OPAT has been noted to be a significant risk factor for
readmission, which may partially explain the difference seen here.8 The potentially
increased debility or acuity of patients more likely to be sent to a SAR center or
ECF, in comparison to a patient able to be sent home, could have also contributed
to this observation; however, an increase in readmission for patients discharged to
these facilities after receiving a consult was not observed.
The need for appropriate monitoring and communication between
healthcare systems should be given careful consideration prior to the
implementation of OPAT. One report noted that 26% of sites surveyed had a team
specifically designated to handle OPAT cases.5 A survey of practitioners involved
in an OPAT service indicated that up to 70% had seen such therapy implemented
without a consult from an ID specialist, and another study showed that the addition
of a pharmacist or ID physician or pharmacist to an OPAT team raised adherence
to monitoring by 32% and 64%, respectively.9,10 One study showed that cases
reviewed by an ID physician led to changes in therapy from parenteral to oral agents
in 27%–40% of cases.9 This shows the value of a dedicated OPAT team’s ability to
improve patient care via appropriate selection of antimicrobial therapy from a
therapeutic perspective, which often reduces costs.
Although poor communication can be a barrier to the success of OPAT,
adverse effects have been cited as the primary reason for OPAT discontinuation or
therapy modification in 3%–5% of cases.9 The rate of readmission, potentially
requiring a change in therapy, in this study for adverse events in the OPAT and
non-OPAT groups was similar to this cited figure, at 3.2% and 4.5%, respectively.
A survey of ID physicians conducted in 2012 showed that only 22% of the OPAT
programs in which they worked had a way to track medication errors, “near
misses,” or adverse events.5 Additionally, it is of utmost importance that patients
who are to receive OPAT be carefully selected to ensure that they have appropriate
social and financial support to receive therapy at home, at an infusion center, or at
another location. The potential ramifications for patients inappropriately selected
for outpatient therapy include both clinical decompensation as well as the potential
for enhanced resistance by the responsible pathogen due to incomplete eradication.
23
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Several limitations should be considered when interpreting the results of
this study. The small sample size and timing of the study period at the advent of the
program could have affected the results. This trend could possibly have been due
to the novelty of the new program or to increased provider confidence in the
utilization of a formalized OPAT program able to more consistently offer improved
monitoring and follow-up after discharge. The lack of assessments related to
appropriateness of therapy, comorbidities, severity of infection, and causative
pathogen limits the generalizability of these findings.
As OPAT services continue to expand in the United States, further
investigations utilizing larger sample sizes and examining shifting trends in patient
outcomes should be conducted in order to further assess the value of the program
and monitor for potential quality-improvement opportunities. Furthermore, patient
and provider satisfaction data could be included to better assess the improvements
in quality of life and perception of value associated with the program. This study
suggests a potential indication for the potential patient-care improvements related
to improved patient outcomes that OPAT services can offer to patients.

24
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